Juying Wei

CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Hui Liu, Wen Lei, Chaoting Zhang et al. · Clinical Cancer Research · 2020 · 146 citations · Full text

Life Sciences, Immunology, Oncology +17

Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

Huafeng Wang, Liping Mao, Min Yang et al. · The Lancet Haematology · 2022 · 107 citations

Medicine, Hematology, Oncology +15

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

Shuo Wang, Li Wang, Jianda Hu et al. · Cancer Communications · 2021 · 35 citations · Full text

Medicine, Immunology, Oncology +15

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Xingnong Ye, Xinping Zhou, Juying Wei et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 31 citations

Medicine, Pharmacology, Pharmacotherapy +16

Geriatric nutritional risk index is not an independent predictor in patients with diffuse large B-cell lymphoma

Zhongqi Li, Qi Guo, Juying Wei et al. · Cancer Biomarkers · 2018 · 28 citations · Full text

Medicine, Hematology, Oncology +17